On the fly News and insights, exclusive to thefly.com



$71.47 /

+35.54 (+98.91%)


Morphic Holding price target raised to $103 from $40 at Wells Fargo

Wells Fargo analyst Yanan Zhu raised the firm's price target on Morphic Holding to $103 from $40 and reiterates an Overweight rating on the shares following the Phase 1 single ascending dose data for the company's oral alpha4-beta7 inhibitor MORF-057 in healthy volunteers. The stock in midday trading is up 133%, or $48.05, to $84.21. The data support MORF-057's product profile as an oral Entyvio, achieving the same level of saturating receptor occupancy as Entyvio, which has roughly $4B in annual sales, along with a "clean" single-dose safety profile, Zhu tells investors in a research note. The analyst believes the data "substantially de-risks" MORF-057 and bodes well for the upcoming data readout from the multiple-ascending dose cohorts in mid-2021.

  • 01


MORF Morphic
$71.47 /

+35.54 (+98.91%)

02/02/21 RBC Capital
Morphic Holding price target raised to $50 from $35 at RBC Capital
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
08/11/20 BMO Capital
Morphic Holding price target raised to $37 from $30 at BMO Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.